Latest Articles
Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025 - Yahoo! Finance Canada
Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025 Yahoo! Finance Canada
Published: Nov. 3, 2025, 1:08 p.m.
Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025 - PR Newswire
Eisai Demonstrates Commitment to Advanced Endometrial Cancer Care at IGCS 2025 PR Newswire
Published: Nov. 3, 2025, 1:08 p.m.
Endometrial Cancer Treatment Market Forecast to grow USD 53.7 Billion by 2035 at a CAGR of 5.3 % | FMI Analysis - industrytoday.co.uk
Endometrial Cancer Treatment Market Forecast to grow USD 53.7 Billion by 2035 at a CAGR of 5.3 % | FMI Analysis industrytoday.co.uk
Published: Oct. 31, 2025, 8:31 a.m.
Endometrial Cancer in Young Women: Insights From a Tunisian Cohort - Cureus
Endometrial Cancer in Young Women: Insights From a Tunisian Cohort Cureus
Published: Oct. 31, 2025, 6:32 a.m.
Hutchmed’s Promising Phase III Study on Advanced Endometrial Cancer Treatment - MSN
Hutchmed’s Promising Phase III Study on Advanced Endometrial Cancer Treatment MSN
Published: Oct. 30, 2025, 10:54 a.m.
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study - MSN
Iovance Biotherapeutics Advances in Endometrial Cancer Treatment with Lifileucel Study MSN
Published: Oct. 30, 2025, 10:49 a.m.
Symptoms of endometrial cancer recurrence: Watch out for unusual weight loss, bleeding, pain, nausea - Moneycontrol
Symptoms of endometrial cancer recurrence: Watch out for unusual weight loss, bleeding, pain, nausea Moneycontrol
Published: Oct. 30, 2025, 8:35 a.m.
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability - MSN
ESMO 2025: MSD and Eisai’s endometrial cancer combo shows five-year durability MSN
Published: Oct. 30, 2025, 4:04 a.m.
Insights into endometrial cancer management: a comprehensive guide through multimodality imaging - springermedicine.com
Insights into endometrial cancer management: a comprehensive guide through multimodality imaging springermedicine.com
Published: Oct. 29, 2025, 10:52 p.m.
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer - BioSpace
CORRECTING and REPLACING Faeth Therapeutics' $92 Million Total Funding Powers PIKTOR Phase 2 Following 80% Response Rate in Endometrial Cancer BioSpace
Published: Oct. 28, 2025, 5:03 a.m.
Link copied to clipboard!